Please ensure Javascript is enabled for purposes of website accessibility

Why Amarin Stock Is Tanking Today

By George Budwell - Aug 9, 2019 at 1:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA will hold an advisory committee meeting after all.

What happened

Shares of Amarin (AMRN -10.04%) are down by a whopping 16.7% as of 12:03 p.m. EDT on Friday. The drugmaker's stock is getting pummeled in response to the news that the Food and Drug Administration (FDA) has indeed decided to convene an advisory committee meeting to discuss the company's proposed label expansion for the prescription omega-3 pill Vascepa. 

A man holding his hand to his forehand with a look of shock on his face. A downward trending chart sits in the background.

Image source: Getty Images.

So what

Last week, Amarin's management noted that an advisory committee meeting was no longer likely in its view, given that the drug's Prescription Drug User Fee Act (PDUFA) goal date of Sept. 28 was less than two months away. So it's not entirely surprising that some investors are heading for the exits in the wake of this unexpected regulatory update.     

Now what

Vascepa's advisory committee meeting is tentatively scheduled for Nov. 14, 2019, according to Amarin's press release. The FDA is therefore expected to extend Vascepa's regulatory timeline beyond the original Sept. 28 PDUFA date. That's not the end of the world, so long as the FDA does eventually green light Vascepa's new label. 

Why is the FDA holding an advisory committee meeting? While the company didn't release any details at this early juncture, the most likely reason is the mineral oil placebo issue.

In Vascepa's large cardiovascular outcomes trial known as Reduce-It, patients in the placebo arm reportedly experienced a noteworthy increase in bad cholesterol levels, which may have exaggerated Vascepa's observed cardio-protective benefits to some degree. On the plus side, this non-inert placebo issue shouldn't turn out to be a showstopper, meaning that bargain hunters may want to take advantage of this sizable drop in Amarin's stock.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
AMRN
$1.49 (-10.04%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.